INDIA FORMULATIONS
Stocks in news: M&M, BHEL, Adani Enterprises, Wipro, Tata Steel, Siemens and Divi's Labs
Indian equity markets ended marginally lower on Sunday, breaking a seven-session winning streak. The NSE Nifty 50 decreased by 44 points, closing at 24,986. Several companies, including Adani Enterprises and Tata Steel, announced important corporate developments and new investments. Wipro appointed a new CEO for its Americas unit, while various firms reported their quarterly earnings. Overall, investors remain cautious as they monitor these announcements and future market movements.
For long- and medium-term investors: Cycles turn, principles don’t; 5 large-cap stocks with upside potential of up to 29%
These are the stocks that fell the most, so they may bounce back the most if the fund flows return. They are the ones FPI money will target first. And they tend to be the businesses with great track records, the ones that have been through bad patches like this before and have come out unscathed. Yes, we are talking about large-cap stocks.
Cancer drug prices to fall by up to 96% from November 9; consumers set to save Rs 3,502 crore annually
Starting November 9, consumers in India will benefit from significantly reduced prices on 137 anti-cancer drugs. The government has capped trade margins on these medications, leading to an estimated annual savings of Rs 3,502.31 crore for consumers. Price reductions have been reported across 1,225 formulations, with some reductions exceeding 50 percent.
Pharma industry steps up API investments to cut import dependence, move up value chain
India's pharmaceutical sector is shifting towards high-value medicines and reducing reliance on imports through local manufacturing. Investments in active pharmaceutical ingredients and advanced therapies are on the rise to meet new healthcare demands. Industry leaders highlight the significance of supply-chain resilience and advancements in manufacturing capabilities. Recent data indicates strong domestic market growth and increasing pharmaceutical exports.
These large-, mid- and small-cap stocks have upside potential of up to 31% in 1 year, according to analysts
In the last two years, the world has learnt that you can never quite predict what US President Trump will do next. Tomorrow, to pull attention one way or another, there could well be some more action against Iran, changing the mood again in a single afternoon. So, the improvement in sentiment is real, but it is also fragile.
India eyes energy self-reliance as supply risks put renewable manufacturing in focus
India must prepare for energy supply disruptions by strengthening domestic renewable energy manufacturing, Union minister Pralhad Joshi said. The country is targeting 500 GW of non-fossil fuel capacity by FY30 and 800 GW by FY35. The government is also drafting guidelines to improve the recyclability of renewable energy equipment.
- Go To Page 1
There is a wider acceptance of hybrid capital with the lack of options beyond bank lending: Bain Capital’s Sarit Chopra
Special Situations team of the Boston based PE group has deployed $1.2 bn in CY26; aims at $1 bn/yr momentum. From funding cross border M&As by India Inc to carve outs or helping promoter’s deleverage their balance sheets, new opportunities are mushrooming.
Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return
In 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic demand alongside enhanced profitability from new product launches. Notable players like Laurus Labs and Gland Pharma have recorded remarkable returns, topping 100%. Amid challenges faced by other sectors, the pharmaceutical field demonstrates resilience. Analysts are optimistic but advise exercising caution regarding potential market volatility and the durability of this sector's performance.
These mid-caps have ‘strong buy’ & ‘buy’ recos and upside potential of up to 28%, according to analysts
Global markets on Wednesday celebrated the outcome of the US mid-term election as well as a sharp drop in oil prices. Oil prices, which at the end of last week were at about $118 to the barrel, are now under $95. The hope clearly is that Democrat control of both chambers of the US Congress will pressure the Trump administration to pursue a diplomatic end to the conflict with Iran in the Gulf.
Kansai Nerolac Q2 net profit rises 8% YoY to Rs 144 crore
Kansai Nerolac Paints announced an 8% increase in net profit for the September quarter. The company reported a revenue rise of over 18% to reach ₹2,317.48 crore. This growth was driven by strong performance in both decorative and industrial segments. The company addressed challenges related to raw material prices and foreign exchange through pricing and cost management efforts.
Zydus Lifesciences Q2 net profit falls 26.6% to Rs 925.5 crore
Zydus Lifesciences reported a net profit of ₹925.5 crore for the September quarter, which declined by 26.6%. The company's revenue from operations increased by 29.2% to ₹7,909.6 crore during the same period. Total expenses rose significantly to ₹6,806.6 crore, impacting profitability. The pharmaceuticals business contributed 83% to overall sales, with revenue from India formulations at ₹1,884.4 crore. North America formulations reported revenue of ₹3,314.5 crore, highlighting strong global performance.
altM raises $10.3 million to scale production of specialty chemicals from agricultural waste
Founded in 2022 by former Tesla manufacturing executives Apoorv Garg and Yugal Raj Jain, altM develops specialty chemicals and biomaterials by converting agricultural residue such as sugarcane bagasse and rice straw into industrial inputs that can replace conventional fossil-derived materials.
Zydus Q2 profit falls 27% despite 29% revenue growth; consumer wellness sales surge 76%
Zydus Lifesciences reported a 29% year-on-year rise in Q2FY27 revenue to Rs 7,909 crore, driven by growth across key markets and a 76% surge in consumer wellness. However, net profit fell 27% to Rs 925 crore, while EBITDA declined 6%. The company continues to advance its specialty drug pipeline.
Nykaa Q2 Results: PAT soars 207% YoY to Rs 101 crore, revenue up 28%; co to acquire 82% stake in Simply Nam
Nykaa reported a 207% year-on-year profit surge to Rs 101 crore in Q2FY27, with revenue rising 28% to Rs 3,006 crore. Beauty and fashion businesses accelerated growth, while quick commerce, owned brands and strategic acquisitions strengthened expansion.
Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%
Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brokerages turned more positive, citing robust international business, improving domestic growth and a strong product pipeline.
High Court restrains NPPA from action against AstraZeneca
The Delhi High Court has issued a temporary restraining order against the NPPA's actions toward AstraZeneca Pharma. This order remains in effect until the next hearing date, January 11. AstraZeneca has argued that its product may not fall under controlled drug prices. The NPPA has accused AstraZeneca of overcharging for the inhaler from May 2016 to November 2025. AstraZeneca denies these allegations and claims compliance with the price regulations.
NEP 2020: Will teacher education reforms miss the bus?
India's teacher education sector faces significant challenges that require immediate reforms to enhance educational quality. The National Education Policy, 2020 emphasises identifying and closing substandard Teacher Education Institutions by 2030. It also calls for standalone institutions to transform into multidisciplinary higher education entities, promoting integrated teacher preparation.
Beauty & personal care brand Hyeglo Beauty raises Rs 7 crore funding led by Sauce
The direct-to-consumer (D2C) will use the funds for research and development (R&D), new product launches, brand building and hiring, as it looks to expand its portfolio, founder Kanupriya Ahluwalia told ET.
NEET-UG 2027 may retain pen-and-paper option as southern states push back against exam overhaul
Centre's proposed examination reforms have encountered resistance from southern states, particularly Tamil Nadu and Kerala, potentially delaying a full transition to computer-based NEET-UG until 2028-29. The Nilekani panel is considering a gradual shift, retaining the pen-and-paper option in 2027 while building consensus and addressing concerns over accessibility.
India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugs
Over the past four quarters, India's medicine sales have increased significantly due to rising demand in chronic care segments. The growth rate reached 12% year-on-year in the September quarter, showing a positive trend in the industry. Larger pharmaceutical companies have benefited from the shutdown of many non-compliant smaller units. Budgets were also boosted by a reduction in GST on medicines.
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%
The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
Sun Pharma Q2 profit takes a hit on exceptional items
Sun Pharmaceutical has seen a notable 36% drop in net profit, juxtaposed with an 11.8% rise in consolidated revenue. The uplift in revenue can be attributed largely to strong sales growth in India and emerging markets, particularly in domestic formulations. Conversely, US formulation sales faced a significant downturn. The company also marked progress in its integration planning for the acquisition of Organon, following the successful completion of regulatory approvals.
Sun Pharma Q2 profit falls 36% as litigation costs hit earnings
Sun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Revenue grew 11.8%, supported by strong domestic and emerging market sales, while US formulations weakened.
Sun Pharma Q2 Results: Profit falls 36% YoY to Rs 1,989 crore on exceptional charges
Sun Pharma Q2 Results: Revenue from operations rose 12% YoY to Rs 16,199 crore from Rs 14,478 crore in Q2 of last financial year, supported by strong growth in its domestic formulations business and emerging markets.
India’s drug pricing policy must balance affordability, medicine availability and pharma industry growth
The Government of India has recently capped trade margins on anti-cancer medicines at 30%. This decision has reignited the ongoing discussion about drug pricing and accessibility. The existing regulatory framework aims to provide affordable medicines while supporting the pharmaceutical industry. Ensuring pricing transparency and targeted interventions can help address excessive margins in the supply chain. The ultimate goal remains to enhance patients' access to quality medicines at reasonable prices.
India's pharma exports rise 4.9% to USD 16.14 bn in H1; shipments to Europe up nearly 10%: Pharmexcil
India's pharmaceutical exports increased nearly 5 percent, reaching USD 16.13 billion in the first half of the fiscal year. Growth was driven by strong demand from Europe, ASEAN, and Latin America. Shipments included drug formulations, biologicals, bulk drugs, and surgical products. Exports to key regions, particularly Europe and ASEAN, rose significantly during this period. Industry leaders emphasized the need for India to enhance its pharmaceutical innovation and manufacturing capabilities.
Actor Imran Khan seeks evidence from FRRO, questions grounds for OCI cancellation amid CEC protest row
Imran Khan has challenged the FRRO's show-cause notice regarding his OCI status, citing incomplete evidence and a lack of transparency. He demands access to all materials used in the decision-making process, arguing that he has not been properly informed of the allegations against him. The Bombay High Court is set to hear the case on Nov 2.
Parliamentary panel to discuss implementation of National Litigation Policy already junked by govt
A parliamentary standing committee will examine the formulation and implementation of a National Litigation Policy in 2026-27, even though the government scrapped the plan in 2025 and instead issued directives to ministries, departments and public sector undertakings to reduce unnecessary court cases.
GSFC plans Jamnagar acid plant to cut fertiliser input import dependence
In a major move, Gujarat State Fertilizers and Chemicals has announced plans to establish a new plant in Jamnagar dedicated to the production of sulphuric and phosphoric acid. This facility will play a crucial role in ensuring the availability of essential raw materials for phosphate fertilizers, particularly in light of increasing prices driven by geopolitical tensions.
Load More
